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Abstract
Background: The tetraspan protein epithelial membrane protein-2 (EMP2), which mediates
surface display of diverse proteins, is required for endometrial competence in blastocyst
implantation, and is uniquely correlated with poor survival from endometrial adenocarcinoma
tumors. Because EMP2 is differentially expressed in the various stages of the murine and human
estrous cycle, we tested the hypothesis that the steroid hormones progesterone and estrogen
influence EMP2 expression and localization.
Methods: Frozen human proliferative and secretory endometrium were collected and analyzed
for EMP2 expression using SDS-PAGE/Western blot analysis. The response of EMP2 to
progesterone and estradiol was determined using a combination of real-time PCR, SDS-PAGE/
Western blot analysis, and confocal immunofluorescence in the human endometrial carcinoma cell
line RL95-2. To confirm the in vitro results, ovariectomized mice were treated with progesterone
or estradiol, and EMP2 expression was analyzed using immunohistochemistry.
Results: Within normal human endometrium, EMP2 expression is upregulated in the secretory
phase relative to the proliferative phase. To understand the role of steroid hormones on EMP2
expression, we utilized RL95-2 cells, which express both estrogen and progesterone receptors. In
RL95-2 cells, both estradiol and progesterone induced EMP2 mRNA expression, but only
progesterone induced EMP2 protein expression. To compare steroid hormone regulation of EMP2
between humans and mice, we analyzed EMP2 expression in ovarectomized mice. Similar to results
observed in humans, progesterone upregulated endometrial EMP2 expression and induced EMP2
translocation to the plasma membrane. Estradiol did not promote translocation to the cell surface,
but moderately induced EMP2 expression in cytoplasmic compartments in vivo.
Conclusion: These findings suggest that targeting of EMP2 to specific locations under the influence
of these steroid hormones may be important for integrating the molecular responses required for
implantation competence.
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Epithelial membrane protein-2 (EMP2) is a tetraspan pro-
tein that plays an important role in the endometrium.
EMP2 is necessary for blastocyst implantation in mice [1],
and aberrant EMP2 expression correlated with poor sur-
vival in endometrial adenocarcinoma patients [2]. Func-
tionally, EMP2 has been shown to play a role in trafficking
of molecules, which include integrins, major histocom-
patibility complex (MHC) class I molecules, and glycosyl-
phosphatidyl inositol (GPI)-anchored proteins, to non-
caveolar glycolipid-enriched lipid rafts [3-5]. These
plasma membrane microdomains are important in the
formation of receptor-protein complexes required for effi-
cient signal transduction. Through this mechanism, EMP2
plays a role in the regulation of cell adhesion and invasion
[3,6,7].
EMP2 is spatially and temporally regulated in the
endometrium. In particular, in the mouse, a prominent
increase in EMP2 expression and translocation to the api-
cal plasma membrane occurred during the window of
implantation, when physiologic effects of estradiol and
progesterone on the endometrium have reached a peak
[1]. Similarly, in the native human endometrium EMP2
expression is minimally detectable during the prolifera-
tive phase, but is much more highly expressed during the
secretory phase [1,2]
Successful implantation of the blastocyst-stage embryo
into the maternal endometrium requires a precise series of
coordinated events [8]. In the endometrium, a number of
specific molecules such as integrins, osteopontin, and the
progesterone receptor have been implicated in implanta-
tion [9], and many of these molecules require estrogen or
progesterone for activation. Endometrial epithelial cells
undergo profound changes during the different phases of
the estrous/menstrual cycles in response to alterations in
circulating levels of estrogen and progesterone. A rising
estrogen level initiates endometrial proliferation and reg-
ulates estrogen target genes in a cell-specific manner [10].
Progesterone, on the other hand, transforms the prolifer-
ative endometrium into secretory endometrium and regu-
lates the expression of genes important for establishing
endometrial receptivity and the progressive phases of
implantation [11]. As the identities of the molecules
important in this transition emerge, a challenge is to
define the mechanisms through which they integrate and
organize these biochemical changes to facilitate blastocyst
attachment and implantation.
The present investigation was carried out to test directly
whether or not the steroid hormones estradiol and pro-
gesterone can account for the temporal and spatial pat-
terns of EMP2 expression. Using protein immunoblot
quantitation, we confirm that EMP2 protein is elevated in
primary human secretory vs. proliferative endometrium.
In the human endometrial cell line RL95-2, EMP2 protein
levels were induced by progesterone alone, a process
inhibitable by progesterone antagonist, and augmented in
combination with estradiol. Similarly, in ovariectomized
mice progesterone specifically increased EMP2 protein
expression and surface translocation, whereas estradiol
had a minimal effect on EMP2 expression and did not
induce surface translocaiton. Thus, steroid hormones
induce deployment of EMP2 in both humans and mice in
a manner consistent with its apparent role as an organizer
of molecular components required for blastocyst implan-
tation.
Methods
Human tissue
Frozen endometrial tissue samples, from proliferative or
secretory phases, were obtained from the UCLA Depart-
ment of Pathology archival biospecimen repository under
Institutional Review Board (IRB) approval. Three prolifer-
ative (subphase unspecified) and three secretory (one
post-ovulatory day 3, one late, one unspecified) phase tis-
sue samples were obtained, homogeneized, and resus-
pended in Laemmli buffer. Samples were analyzed for
EMP2 expression by SDS-PAGE as outlined below.
Cell line and hormone treatment in vitro
RL95-2 (ATCC, Manassas, VA), a well-differentiated
endometrial adenocarcinoma cell line, was cultured in a
1:1 mixture of Dulbecco's modified Eagle's medium and
Ham's F12 medium supplemented with 10 mM HEPES,
2.0 g/L sodium bicarbonate, 0.005 mg/ml insulin, 10%
fetal calf serum (Hyclone Laboratories, Logan, Utah), 2
mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml pen-
icillin, and 100 U/ml streptomycin (all from Invitrogen
Life Technologies). For hormone treatment, RL95-2 cells
at 60–70% confluence were washed in PBS, and subse-
quently incubated with steroid hormones in treatment
medium (DMEM/Ham's F-12 supplemented with 0.5%
charcoal-stripped FBS [Omega Scientific, Tarzana, CA],
1% penicillin-streptomycin, and 1% L-glutamine). Pro-
gesterone and 17β-estradiol (Sigma Corp., St. Louis, MO)
were prepared in 1000-fold concentrated stocks in abso-
lute ethanol, and added to treatment medium to yield a
final ethanol concentration of 0.1%. In some experi-
ments, cells were incubated with progesterone in combi-
nation with a progesterone receptor antagonist
(mifepristone (RU 486); Sigma). The treatment times and
drug concentrations for each experiment are indicated in
the text and/or figure legends.
Quantitative RT-PCR
Quantitative real-time RT-PCR was performed on the iso-
lated RNA by using the Quantitect probe RT-PCR kit (QIA-
GEN, Valencia, CA) on the DNA Engine Opticon MonitorPage 2 of 11
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genomic RNA detection, the long terminal repeat (LTR)
forward primer (5'-TCCTCTCCACCATTCTCT-3'), LTR
reverse primer (5'-AAACCTCTCTCCCTGCTTCA-3'), and
the fluorogenic probe (6-carboxyfluorescein [6FAM]-5'-
TTCTTCATCTTCGTGCT-3'-tetramethyl carboxyrhodam-
ine [TAMRA]) were utilized for the RT-PCR. The quantity
of EMP2 was calculated by interpolation from a standard
curve generated by running in parallel serial dilutions of
known quantities of full length EMP2 cDNA incorporated
into the EGFP-N3 vector. The EMP2 signals were normal-
ized against the housekeeping gene GAPDH using the
Qiagen GAPDH Assay on Demand which included both
primers and probe. The β-actin copy number was also cal-
culated by interpolation from a standard curve generated
from serial dilutions of a plasmid containing GAPDH
cDNA (clone3869809; Open Biosystems, Huntsville, AL)
Antibodies
Rabbit polyclonal antibodies generated against human or
mouse EMP2 (hEMP2 or mEMP2, respectively) have been
described previously [7,12]. Commercial antibodies used
included estrogen receptor (ER) and progesterone recep-
tor (PR) antibodies (all from Santa Cruz Biotechnology,
Santa Cruz, CA), γ-adaptin antibodies (BD Biosciences,
San Diego, CA) and horseradish peroxidase-conjugated
secondary antibodies (1:1500; BD Biosciences; Southern
Biotechnology Associates, Birmingham, AL). Normal rab-
bit sera were used as negative controls for the primary
antibody.
Immunoblot analysis
Cells were washed in PBS, collected, and resuspended in
Laemmli buffer. To detect EMP2 expression, cell extracts
were treated with peptide N-glycosidase F (New England
Biolabs, Beverly, MA) to deglycosylate the proteins as pre-
viously described [7]. The lysates were separated on a 12%
SDS-PAGE gel, and proteins were transferred to nitrocellu-
lose (Bio-Rad Laboratories, Hercules, CA). EMP2 was
detected using primary hEMP2 (1:2000) antisera followed
by a horseradish peroxidase-conjugated goat anti-rabbit
IgG and ECL detection reagents (Amersham-Pharmacia,
Piscataway, NJ).
Confocal microscopy
RL95-2 cells were plated onto glass coverslips (Fisher Sci-
entific, Pittsburgh, PA) overnight. Cells were washed in
PBS and then incubated for 48 hours with 25 µM proges-
terone, 20 µM estradiol, or a vehicle control in the treat-
ment media described above. Cells were fixed and
permeabilized in methanol at -20°C for 30 min and rehy-
drated in PBS. Cells were blocked in 1% normal goat
serum for 45 min and incubated overnight at 4°C with the
EMP2 rabbit sera (1:250) and an anti-γ-adaptin antibody
(1:200) in a humidified chamber. Cells were rinsed with
PBS + 0.01% Triton X-100, then incubated (2–4 hours. at
RT) with fluorescein isothiocyanate (FITC)-conjugated
goat anti-rabbit IgG (1:50) or Rhodamine-conjugated
donkey anti-mouse IgG (1:500; Jackson ImmunoResearch
Laboratories, West Grove, PA). Negative controls included
incubation of cells with secondary antibody alone. Cells
were copiously washed in PBS + 0.01% Triton, rinsed
briefly with double deionized H20, and mounted in a
3.5% n-propyl gallate-glycerol solution.
Confocal pictures were taken using a Zeiss LSM 510 con-
focal microscope at 600× magnification. The colocaliza-
tion coefficient between EMP2 and γ-adaptin was
determined using Zeiss LSM 5 PASCAL software (Carl
Zeiss MicroImaging GmbH, Germany), and values repre-
sent the relative number of colocalizing pixels of γ-adap-
tin compared to the total number of pixels above
threshold. The mean colocalization coefficient was aver-
aged from at least 3 independent images.
Animals and hormone treatment in vivo
All animals used in this study were maintained in accord-
ance with the National Academy of Science Guide for the
Care and Use of Laboratory Animals, with a controlled light
schedule (14L:10D) and controlled temperature range.
Ovariectomized female CF-1 mice (Harlan Sprague-Daw-
ley, Indianapolis, Indiana) were treated with daily injec-
tions of 100 ng per mouse of 17β estradiol or 1 mg per
mouse of progesterone dissolved in 100 µL of sesame oil,
or sesame oil alone (Sigma) as previously described [13].
Mice were euthanized at various time points (indicated in
text or legends), and the uteri were processed for immu-
nohistochemistry using mEMP2 antisera or control rabbit
serum. Tissue blocks were immunostained as outlined
below.
Immunohistochemistry
Uterine tissue was stained as previously described [1].
Briefly, uterine tissue was fixed in 10% formalin, embed-
ded in paraffin, and sectioned at 5 µm thickness. Antigen
retrieval was performed using 0.1 M citrate, pH 6.0, at
95°C for 20 min. The slides were incubated with mEMP2
antisera (1:250) or control rabbit serum at the same dilu-
tion overnight. The antibody signal was visualized using
the Vectastain ABC kit (Vector Labs, Burlingame, CA)
according to the manufacturer's instructions. EMP2
expression was detected using diaminobenzidine. Nuclei
were counterstained using hemotoxylin.
Statistics
Differences in EMP2 expression levels between test and
vehicle control groups were evaluated using an unpaired
student's t test at a 95% confidence level (GraphPad Prism
version 3.0; GraphPad Software, San Diego, CA). To com-Page 3 of 11
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using GraphPad Prism software.
Results
EMP2 expression in human tissue
EMP2 expression varies both temporally and spatially
during the murine estrous and human menstrual cycles,
suggesting that it is regulated by the steroid hormones
progesterone and estradiol. To determine the expression
of EMP2 in the human endometrium, tissues were
obtained from normal patients in either the proliferative
(n = 3, subphase unspecified) or secretory (n = 3; one
post-ovulatory day 3, one late, one unspecified) phase of
the estrous cycle. Expression in the lung was provided as a
control, as it is the site of highest EMP2 expression [7]. As
shown in Fig. 1, EMP2 expression was strikingly upregu-
lated (3-fold) in secretory versus proliferative
endometrium (p = 0.038).
Effect of steroid hormones on EMP2 mRNA and protein 
levels in vitro
To assess the regulation of EMP2 expression, the well-dif-
ferentiated endometrial adenocarcinoma cell line RL95-2
was utilized. RL95-2 cells express EMP2 [1] and steroid
hormone receptors [14,15], and these results were vali-
dated by SDS-PAGE/Western blot analysis (Figure 2A). In
order to elucidate the regulation of EMP2 by steroid hor-
mones, estradiol, progesterone, or a vehicle control added
to RL95-2 cells for 1–12 hours. Cells were harvested at dif-
ferent times, and analyzed using quantitative RT-PCR. As
seen in Figure 2B, estradiol or progesterone alone mod-
estly increased EMP2 mRNA, to levels that were non-sig-
nificant or minimally significant by ANOVA (p = 0.3 and
0.02, respectively). The combination of estradiol and pro-
gesterone produced a similarly modest increase, but one
which was more statistically significant (p = 0.002; Figure
2C).
To characterize the effects of progesterone and estradiol
on EMP2 with respect to protein expression, steroid hor-
mones were added individually or in combination to
RL95-2 cells for 72 h. EMP2 expression was significantly
induced by progesterone (2.5-fold compared to vehicle
control), and the receptor selectivity of this response was
confirmed by suppression of this response in the presence
of mifespristone (RU 486), a progesterone receptor antag-
onist (Fig. 3A,B). In contrast to progesterone, estradiol
alone slightly reduced EMP2 expression compared to the
vehicle control. Combining estradiol with progesterone
numerically augmented the increased in EMP2 protein
observed with progesterone alone (4-fold compared to
vehicle control). This response was not taken to be syner-
(A) Normal human endometrium specimens from subjects in proliferative and secretory phases were immunoblotted using EMP2 antiseraFigure 1
(A) Normal human endometrium specimens from subjects in proliferative and secretory phases were immunoblotted using 
EMP2 antisera. β-actin was used as a loading control. (B) Statistical analysis of EMP2 expression levels in proliferative (n = 3: 
subphase unspecified) and secretory (n = 3: one post-ovulatory day 3, one late, one unspecified) endometrial specimens from 
six independent patients. Data were analyzed using a 2-tailed, unpaired student t-test with a 95% confidence interval. *Changes 
in expression between the proliferative and secretory endometrium were significant, p = 0.038.
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progesterone treatment alone and a combination of pro-
gesterone and estrogen treatment (p = 0.30). These find-
ings suggest that progesterone largely accounts for the
increase in EMP2 expression observed during the secre-
tory phase of the cycle in mice and in humans [1,2]. In
view of the much smaller mRNA changes, these protein
findings suggest that EMP2 regulation by progesterone
may be indirect (presumably by primarily targeting other
cellular processes affecting post-translational fate of
EMP2).
To further quantitate the effects of progesterone on EMP2
protein expression, RL95-2 cells were exposed to different
concentrations of progesterone ranging from 0.5–100 µM
for 72 h. EMP2 expression was selectively induced with
progesterone at concentrations between 10 and 50 µM
(Fig. 3C,D). Notably, progesterone at a 100 µM concentra-
tion induced ~50% cell death as indicated by trypan blue
staining (data not shown). This toxicity probably
accounted for the reduced EMP2 induction at this hor-
mone concentration (Fig. 3C,D).
Progesterone increases the surface expression of EMP2 in 
vitro
To determine the localization of EMP2 protein following
hormone treatment, RL95-2 cells were stained and ana-
lyzed by confocal immunofluorescence (Fig. 4). Cells
were cultured in media containing charcoal stripped FBS
and a vehicle control, progesterone, or estradiol for 24
hours. Cells were then stained for both EMP2 and the
Golgi apparatus marker, γ-adaptin, as previous studies
had suggested that EMP2 resides in this intracellular com-
partment [4].
The results of this analysis are shown in Figure 4. In vehi-
cle control cells, the majority of EMP2 appeared to reside
in intracellular compartments, with 31.7 ± 2% of total
EMP2 colocalizing within the Golgi apparatus. As previ-
ously described, some EMP2 localization was also detect-
able on the plasma membrane [1]. Following estradiol
treatment, less EMP2 was observed on the plasma mem-
brane, with most EMP2 detectable in intracellular com-
partments, including increased colocalization in the Golgi
apparatus (42.5 ± 4% of total EMP2) (Fig. 4). In contrast,
following progesterone treatment, expression of EMP2
was observed predominantly on the plasma membrane.
Quantitatively, this is reflected by the reduced localization
Steroid hormones induce EMP2 mRNA expression in RL95-2 cellsFigure 2
Steroid hormones induce EMP2 mRNA expression in RL95-2 cells. (A) Validation of hormone receptor status of RL95-2 cells. 
Cell extracts were processed by SDS-PAGE and Western blot for detection of EMP2, ER, and PR protein expression. (B and 
C) Temporal effect of hormone treatment in RL95-2 cells on EMP2 mRNA. RL95-2 cells were cultured with 20 µM estradiol 
and/or 25 µM progesterone. After 1–12 h, extracts from hormone-treated cells were obtained, mRNA was isolated, and EMP2 
transcript levels were quantitated by quantitative RT-PCR. Results are expressed as the percentage increase of EMP2 over the 
vehicle control, and represent the average of 3 independent experiments. Error bars are SEM; p values were calculated by 
ANOVA. (B) EMP2 mRNA expression in response to progesterone or estradiol are alone. (C) EMP2 mRNA expression in 
response to a combination of estradiol and progesterone.
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Reproductive Biology and Endocrinology 2008, 6:15 http://www.rbej.com/content/6/1/15of EMP2 in the Golgi apparatus (28.0% ± 0.4 of total
EMP2).
Steroid hormone effects on EMP2 expression and surface 
expression in native mouse endometrium in vivo
To extend these observations to native endometrium, we
determined the effects of estradiol and progesterone on
EMP2 expression in the uteri of ovariectomized mice.
Three to five weeks after ovariectomy, mice were injected
daily for up to 5 days (days 0–4) with estradiol, progester-
one, or sesame oil, the vehicle used for dissolving the ster-
oid hormones. Uteri were harvested on days 1, 2, 4, and 7
after initiating treatment (note that day 7 was 3 days fol-
lowing the last hormone injection) and then stained for
EMP2 expression.
Progesterone induces EMP2 expression in RL95-2 cellsFigure 3
Progesterone induces EMP2 expression in RL95-2 cells. (A) Western immunoblots for EMP2 from extracts of RL95-2 cells cul-
tured for 72 h with 25 µM progesterone (P), 20 µM estradiol (E), P plus E, P plus 100 nM mifepristone, or a vehicle control 
(VC; ethanol). Western immunoblot for β-actin was used as a loading control. (B) Western immunoblots from hormone-
treated RL95-2 cells were quantitated for EMP2, normalized for β-actin, and data from three or more experiments were tabu-
lated for mean and SEM. *Changes in EMP2 expression between progesterone treatment and the vehicle control were signifi-
cant, p = 0.03. (C) RL95-2 cells were cultured with the indicated concentrations of progesterone (P) for 72 h, and EMP2 and β-
actin expression were detected by Western immunoblots. (D) Quantitative analysis of the EMP2 response to varying concen-
trations of progesterone, performed as described in (B). *Changes in EMP2 expression were significant compared to the vehi-
cle control, p < 0.05. All experiments were repeated at least 3 times with similar results.
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Reproductive Biology and Endocrinology 2008, 6:15 http://www.rbej.com/content/6/1/15At baseline (3–5 weeks after ovariectomy), EMP2 was not
detected in the endometrium (data not shown). Within
24 h of progesterone injection, EMP2 was clearly detected
in the glandular epithelium, but was only faintly detected
Progesterone induces surface expression of EMP2 in RL95-2 cellsFigure 4
Progesterone induces surface expression of EMP2 in RL95-2 cells. RL95-2 cells were treated for 72 hours with 25 µM proges-
terone, 20 µM estradiol, or a vehicle control, and processed for confocal microscopy with antibodies for EMP2 (FITC) and γ-
adaptin (Rhodamine). Images were captured at a magnification of 600×. Scale bar, 10 µM. The experiment was repeated at least 
3 times with similar results.
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48 h of progesterone injection, EMP2 expression on the
apical plasma membrane of the luminal and glandular
epithelium increased significantly (Fig. 5B); this increase
persisted through day 4 of treatment (Fig. 5C). However,
three days following completion of progesterone treat-
ment (day 7), EMP2 protein was no longer detected at the
apical plasma membrane, but was still observed in cyto-
plasmic compartments of both luminal and glandular
epithelium (Fig. 5D). These changes in EMP2 expression
were specific to progesterone as evidenced by the absence
of an effect after injection solely of the vehicle control
(Fig. 5E).
Treatment of ovariectomized mice with estradiol only
modestly affected EMP2 expression in native
endometrium (Fig. 6). No EMP2 expression was observed
within 24 h of estradiol treatment (Fig. 6A). However,
daily injection of 100 ng estradiol induced faint EMP2
expression by 48 h after initiating treatment (Fig. 6B).
EMP2 expression was more prominent by day 4 of treat-
ment (Fig. 6C), but was no longer observed 3 days follow-
ing completion of treatment (Fig. 6D). No staining was
observed with rabbit isotype control as the primary anti-
body (Fig. 6E). In contrast to progesterone, estradiol
induced EMP2 expression only within the cytoplasmic
compartment and not at the apical plasma membrane.
That is, estradiol did not induce translocation of EMP2 to
the plasma membrane surface during this experimental
window.
Discussion
Previous studies in a number of cell types suggest that
EMP2 functions as a trafficking molecule, promoting the
surface expression of cohort proteins such as integrins,
GPI-anchored proteins, and MHC class I molecules [1,3-
5]. In the endometrium, EMP2 expression modulates
αvβ3 integrin expression, and EMP2 is required for suc-
cessful implantation [1,3]. Moreover, dysregulation of
EMP2 has been linked to endometrial adenocarcinoma,
where upregulation of EMP2 is a prognostic indicator of
advanced or high grade disease [2]. Because the estrous/
menstrual cycle appears to regulate EMP2 expression in
both mouse and human [1,2], we examined the role of
steroid hormones in EMP2 regulation. In this report, we
investigate the regulation of EMP2 using a combination of
archived human tissue, the human endometrial cancer
cell line RL95-2 in vitro, and hormonally manipulated
native mouse endometrium in vivo. Our findings with
these three biologic systems were consistent with the con-
clusion that progesterone significantly influences the pro-
tein expression and surface localization of EMP2.
In native human endometrial specimens, EMP2 protein
was highly expressed in secretory human endometrium, at
levels 3-fold higher than in proliferative endometrium.
This secretory phase response suggested a role for proges-
terone and/or estradiol, and their relative contributions
were assessed using the human RL95-2 cell line in vitro. In
these cells, EMP2 protein was increased 2.5- to 4-fold after
hormone treatment (72 hours). This response was
dependent on progesterone, inhibitable by progesterone
antagonist, and neither replicated by estradiol alone nor
augmented in combination with estradiol. The same hor-
monal features (progesterone dependence, inhibition by
progesterone antagonist, and minimal estradiol effect)
were observed by immunohistochemical analysis of
EMP2 protein expression in native endometrium of ova-
riectomized mice.
Mechanistically, this hormonal response did not appear
to particularly involve transcriptional control, since EMP2
mRNA expression in RL95-2 cells was only modestly
upregulated by progesterone or estradiol, reaching a peak
at 4 hours after induction (~1.5-fold of vehicle control).
These protein and mRNA results suggest that the EMP2
expression was predominantly controlled by progesterone
rather than estradiol, and probably largely through a post-
transcriptional effect of progesterone signaling on cellular
processes that secondarily affected EMP2 protein levels.
In native mouse endometrium, previous studies have
shown that EMP2 protein is expressed in a cytoplasmic
pattern early in estrous/menstrual cycle, and on the
plasma membrane during the window of implantation
[1,2]. These findings had suggested that in addition to
expression levels, hormonal induction of the
endometrium might also elicit EMP2 translocation. This
prediction was confirmed in the present study by laser
confocal and conventional immunohistochemistry. Hor-
mone treatment of RL95-2 cells induced a shift of EMP2
from a predominantly cytoplasmic to surface localization,
in a process dependent on progesterone, inhibitable by
progesterone antagonist, and unaffected by estradiol.
Similarly, hormone treatment of native endometrium of
ovariectomized mice in vivo also induced dramatic surface
localization of EMP2, whereas estradiol had no effect on
EMP2 surface translocation. The progesterone-induced
translocation began at day 2 after treatment, suggesting
that progesterone activates a molecular trafficking process
required for efficient delivery of EMP2 to the cell surface.
While the ligated progesterone receptor elicits profound
changes in the cellular transcription program [16-19], we
are not aware of studies that have delineated within this
program a progesterone-induced membrane transloca-
tion system.
During implantation, hormonal and local signals instruct
endometrial cells to acquire receptivity during the brief
implantation window. Given the importance of EMP2 inPage 8 of 11
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Progesterone induces surface expression of EMP2 in mouse endometrium in vivoFigure 5
Progesterone induces surface expression of EMP2 in mouse endometrium in vivo. Mice were injected with progesterone or 
sesame oil (control) daily for up to 5 days. Tissue was harvested at days 1, 2, and 4 of treatment or 3 days following completion 
of treatment, processed for immunohistochemistry, and then stained for EMP2 expression (A-D) or a vehicle control (E). (A) 
24 hours of progesterone treatment; (B) 48 hours of treatment; (C) 4 days of treatment; (D) 3 days following treatment; (E) 
representative control treatment at 4 days. Magnification: (left) 100×; (right) 400×. The experiment was repeated at least 3 
times with similar results; representative images are shown.
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Estradiol induces cytoplasmic expression of EMP2Figure 6
Estradiol induces cytoplasmic expression of EMP2. Mice were injected daily with estradiol for up to 5 days. Tissue was har-
vested at days 1, 2, and 4 of treatment or 3 days following estradiol treatment, processed for immunohistochemistry and 
stained with EMP2 antisera (A-D) or preimmune serum (E). (A) 24 hours of estradiol treatment; (B) 48 hours of estradiol 
treatment; (C) 4 days of estradiol treatment; (D) 3 days following estradiol treatment. (E) Representative isotype control at 48 
hours of estradiol treatment. 100× (left side) and 400× (right side) images are provided. The experiment was repeated 3 times, 
and representative images are shown.
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regulating αvβ3 integrin, GPI-APs, and MHC I, the regula-
tion of EMP2 is important to understanding the complex
changes that occur during the implantation window. If
EMP2 expression is an important physiologic switch for
implantation competence, this implies that infertility in
some cases may be due to genetic or biologic impairments
in the program of endometrial EMP2 expression. Accord-
ingly, agents that might overcome impaired EMP2 expres-
sion in the uterus could be therapeutically useful.
Additional experiments will be important to validate the
role of EMP2 in the implantation window.
Abbreviations
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